Spots Global Cancer Trial Database for metastatic neoplasm
Every month we try and update this database with for metastatic neoplasm cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
| Study title | NCT ID | Conditions | Interventions | Eligibility | Organization | Link |
|---|---|---|---|---|---|---|
| A First-in-Human Dose Escalation and Expansion Study to Evaluate Intratumoral Administration of SAR441000 as Monotherapy and in Combination With Cemiplimab in Patients With Advanced Solid Tumors | NCT03871348 | Metastatic Neop... | SAR441000 Cemiplimab REGN... | 18 Years - | Sanofi | |
| Safety and Efficacy Study of SAR442720 in Combination With Other Agents in Advanced Malignancies | NCT04418661 | Metastatic Neop... | SAR442720 Pembrolizumab Adagrasib | 18 Years - | Sanofi | |
| Dalteparin in Preventing DVT in Participants With Cancer | NCT00525057 | Bone Sarcoma Femur Fracture Lymphoma Metastatic Neop... Pathologic Frac... Plasma Cell Mye... Soft Tissue Sar... | Dalteparin | 30 Years - | M.D. Anderson Cancer Center | |
| Safety and Efficacy Study of SAR442720 in Combination With Other Agents in Advanced Malignancies | NCT04418661 | Metastatic Neop... | SAR442720 Pembrolizumab Adagrasib | 18 Years - | Sanofi | |
| Dalteparin in Preventing DVT in Participants With Cancer | NCT00525057 | Bone Sarcoma Femur Fracture Lymphoma Metastatic Neop... Pathologic Frac... Plasma Cell Mye... Soft Tissue Sar... | Dalteparin | 30 Years - | M.D. Anderson Cancer Center | |
| A First-in-Human Dose Escalation and Expansion Study to Evaluate Intratumoral Administration of SAR441000 as Monotherapy and in Combination With Cemiplimab in Patients With Advanced Solid Tumors | NCT03871348 | Metastatic Neop... | SAR441000 Cemiplimab REGN... | 18 Years - | Sanofi | |
| Margetuximab Plus Chemotherapy vs Trastuzumab Plus Chemotherapy in the Treatment of HER2+ Metastatic Breast Cancer | NCT02492711 | HER-2 Positive ... Metastatic Neop... | Margetuximab Trastuzumab Physician's cho... | 18 Years - | MacroGenics | |
| Long-term Outcome of HER2-amplified Metastatic Breast Cancer: A Retrospective Analysis | NCT02560311 | ERBB2 Breast Cancer Metastatic Neop... | observation | - | University of Zurich | |
| Phase 2 Basket Trial of Nab-sirolimus in Patients With Malignant Solid Tumors With Pathogenic Alterations in TSC1/TSC2 Genes (PRECISION 1) | NCT05103358 | Tumor Tumor, Solid Metastasis Metastatic Canc... Cancer Cancer Metastat... Tumors Neoplasms Neoplasm Metast... Solid Tumor Advanced Solid ... Advanced Cancer Malignant Solid... Malignant Solid... Malignant Neopl... Malignant Tumor TSC TSC1 TSC2 Metastatic Soli... Metastatic Neop... | nab-sirolimus | 12 Years - | Aadi Bioscience, Inc. | |
| Phase 2 Basket Trial of Nab-sirolimus in Patients With Malignant Solid Tumors With Pathogenic Alterations in TSC1/TSC2 Genes (PRECISION 1) | NCT05103358 | Tumor Tumor, Solid Metastasis Metastatic Canc... Cancer Cancer Metastat... Tumors Neoplasms Neoplasm Metast... Solid Tumor Advanced Solid ... Advanced Cancer Malignant Solid... Malignant Solid... Malignant Neopl... Malignant Tumor TSC TSC1 TSC2 Metastatic Soli... Metastatic Neop... | nab-sirolimus | 12 Years - | Aadi Bioscience, Inc. | |
| Genomic Sequencing in Determining Treatment in Patients With Metastatic Cancer or Cancer That Cannot Be Removed by Surgery | NCT02566421 | Metastatic Neop... Recurrent Neopl... Recurrent Non-S... Stage IIIA Non-... Stage IIIB Non-... Stage IV Non-Sm... Unresectable Ma... | Laboratory Biom... Quality-of-Life... Targeted Therap... | 18 Years - | Wake Forest University Health Sciences | |
| Bevacizumab-containing Regimen for Metastatic Colorectal Cancer Failed to Cytotoxic Treatment | NCT02226289 | Neoplasm Colorectal Canc... Metastatic Neop... | Bevacizumab | 18 Years - | Sixth Affiliated Hospital, Sun Yat-sen University | |
| Bevacizumab-containing Regimen for Metastatic Colorectal Cancer Failed to Cytotoxic Treatment | NCT02226289 | Neoplasm Colorectal Canc... Metastatic Neop... | Bevacizumab | 18 Years - | Sixth Affiliated Hospital, Sun Yat-sen University | |
| Gene-Modified T Cells, Vaccine Therapy, and Nivolumab in Treating Patients With Stage IV or Locally Advanced Solid Tumors Expressing NY-ESO-1 | NCT02775292 | Adult Solid Neo... Childhood Solid... Metastatic Neop... | Aldesleukin Cyclophosphamid... Fludarabine Pho... Laboratory Biom... Nivolumab NY-ESO-1 Reacti... NY-ESO-1(157-16... Positron Emissi... | 16 Years - | Jonsson Comprehensive Cancer Center | |
| Gene-Modified T Cells, Vaccine Therapy, and Nivolumab in Treating Patients With Stage IV or Locally Advanced Solid Tumors Expressing NY-ESO-1 | NCT02775292 | Adult Solid Neo... Childhood Solid... Metastatic Neop... | Aldesleukin Cyclophosphamid... Fludarabine Pho... Laboratory Biom... Nivolumab NY-ESO-1 Reacti... NY-ESO-1(157-16... Positron Emissi... | 16 Years - | Jonsson Comprehensive Cancer Center |
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
